Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Follicular Lymphoma
Ann Arbor Stage II Marginal Zone Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Follicular Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Parsaclisib
Biological: Pegfilgrastim
Drug: Polatuzumab Vedotin
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2020-03-27

Last Posted Date: 2023-10-30

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT04323956

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2

Recruiting

Conditions: Anaplastic Kidney Wilms Tumor
Stage III Kidney Wilms Tumor
Recurrent Kidney Wilms Tumor
Stage II Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Ifosfamide
Drug: Irinotecan
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Procedure: Surgical Procedure
Procedure: Transabdominal Ultrasound
Drug: Topotecan
Drug: Vincristine
Procedure: X-Ray Imaging

First Posted Date: 2020-03-26

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 221

Registration Number: NCT04322318

Locations: 🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States

and more 193 locations

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Non Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: TC-110 T Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-03-26

Last Posted Date: 2023-03-16

Lead Sponsor: TCR2 Therapeutics

Target Recruit Count: 6

Registration Number: NCT04323657

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1

Completed

Conditions: HER2-positive Gastric Cancer
HER2-positive Metastatic Breast Cancer
Locally Advanced Solid Tumor
Solid Tumor
Metastatic Cancer

Interventions: Drug: ACE1702
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-03-24

Last Posted Date: 2024-12-05

Lead Sponsor: Acepodia Biotech, Inc.

Target Recruit Count: 12

Registration Number: NCT04319757

Locations: 🇺🇸
Northwestern Univeristy, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳
Taipei Veteran General Hospital, Taipei, Taiwan

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Phase 1

Active, not recruiting

Conditions: BPDCN
B-ALL
AML/MDS
T-ALL

Interventions: Drug: CD123-CAR T
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Drug: Rituximab

First Posted Date: 2020-03-24

Last Posted Date: 2024-08-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT04318678

Locations: 🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Cyclophosphamide
Biological: Multiple Signals loaded Dendritic Cells Vaccine

First Posted Date: 2020-03-23

Last Posted Date: 2020-10-29

Lead Sponsor: Yuehua Huang

Target Recruit Count: 600

Registration Number: NCT04317248

Locations: 🇨🇳
Sun Yat-sen University Cancer center, Guangzhou, Guangdong, China
🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China

and more 1 locations

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lenzilumab
Biological: Axicabtagene Ciloleucel

First Posted Date: 2020-03-19

Last Posted Date: 2024-03-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 6

Registration Number: NCT04314843

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York, United States

and more 7 locations

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Phase 1

Conditions: CD19-positive ALL

Interventions: Biological: anti-CD19/CD22 CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-03-11

Last Posted Date: 2020-03-11

Lead Sponsor: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

Target Recruit Count: 20

Registration Number: NCT04303520

Locations: 🇨🇳
Henan Province of TCM, Zhengzhou, Henan, China

Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

Phase 2

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Capecitabine
Drug: Cyclophosphamide

First Posted Date: 2020-03-11

Last Posted Date: 2023-06-28

Lead Sponsor: European Institute of Oncology

Target Recruit Count: 162

Registration Number: NCT04304352

Locations: 🇮🇹
European Institute of Oncology, Milan, Italy

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Phase 1

Recruiting

Conditions: Adult T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma
HTLV-1 Infection
Chronic Adult T-Cell Leukemia/Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2020-03-09

Last Posted Date: 2024-07-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT04301076

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy